600557 Jiangsu Kanion Pharmaceutical
- 17.66
- -0.16-0.90%
Jiangsu Kanion Pharmaceutical News
Does Jiangsu Kanion PharmaceuticalLtd (SHSE:600557) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. Sometime
Kangyuan Pharmaceutical (600557.SH) will distribute the 2023 cash dividend of 0.37203 yuan per share on May 31
Kangyuan Pharmaceutical (600557.SH) announced that the company will release the 2023 fiscal year on May 31, 2024...
China Merchants Securities: The 24Q1 Chinese medicine sector has steadily overcome high base pressure, and profit levels and dividends have improved markedly
The traditional Chinese medicine industry was slightly under pressure due to high base pressure in the short term, but the level of profit and dividends performed well. In the context of policies encouraging the inheritance, innovation and development of traditional Chinese medicine, along with the reform of state-owned enterprises and the implementation of catalytic events such as the basic drug catalogue, the traditional Chinese medicine sector is still cost-effective.
Jiangsu Kanion Pharmaceutical Co.,Ltd.'s (SHSE:600557) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Most readers would already be aware that Jiangsu Kanion PharmaceuticalLtd's (SHSE:600557) stock increased significantly by 15% over the past three months. We wonder if and what role the company's fi
Kangyuan Pharmaceutical (600557.SH): A total cost of 17.34 million yuan to buy back 0.1733% of shares
Gelonghui, May 7, 丨 Kangyuan Pharmaceutical (600557.SH) announced that as of April 30, 2024, the company had repurchased a total of 1,013,600 shares, accounting for 0.1733% of the company's total share capital. The highest purchase price was 19.83 yuan/share, the lowest price was 16.27 yuan/share, and the total amount paid was 17,344,891.23 yuan (including transaction fees).
Jiangsu Kanion PharmaceuticalLtd's (SHSE:600557) Earnings May Just Be The Starting Point
Jiangsu Kanion Pharmaceutical Co.,Ltd.'s (SHSE:600557) earnings announcement last week was disappointing for investors, despite the decent profit numbers. We have done some analysis and have found so
Kangyuan Pharmaceutical (600557.SH): Net profit of 148 million yuan in the first quarter increased 4.67% year-on-year
Gelonghui, April 12 | Kangyuan Pharmaceutical (600557.SH) released its first quarter report. Operating revenue was 1,359 million yuan, up 0.48% year on year, net profit of 148 million yuan, up 4.67% year on year, after deducting non-net profit of 140 million yuan, up 0.20% year on year, with basic earnings per share of 0.26 yuan.
Is There An Opportunity With Jiangsu Kanion Pharmaceutical Co.,Ltd.'s (SHSE:600557) 36% Undervaluation?
Key Insights The projected fair value for Jiangsu Kanion PharmaceuticalLtd is CN¥31.77 based on 2 Stage Free Cash Flow to Equity Current share price of CN¥20.20 suggests Jiangsu Kanion Pharmaceutica
Kangyuan Pharmaceutical (600557.SH): A total cost of 14.12 million yuan to buy back 0.15% of shares
Gelonghui, April 1, 丨 Kangyuan Pharmaceutical (600557.SH) announced that as of March 31, 2024, the company had repurchased a total of 849,300 shares, accounting for 0.15% of the company's total share capital. The highest transaction price purchased was 17.93 yuan/share, the lowest transaction price was 16.27 yuan/share, and the total amount paid was 14,121,888.36 yuan.
Kangyuan Pharmaceutical (600557.SH): Received an approval notice for clinical trials of injectable AAPB
Gelonghui, March 28, 丨 Kangyuan Pharmaceutical (600557.SH) announced that it has recently received the “Drug Clinical Trial Approval Notice” for Class 1 AAPB (two specifications) for injecting new chemical drugs issued by the State Drug Administration. Injectable AAPB is a novel anti-ischemic stroke neuroprotector jointly developed by the company and China Pharmaceutical University. The formulation specifications are 10 mg and 25 mg, and clinically intended for acute ischemic stroke.
Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) Yearly Results: Here's What Analysts Are Forecasting For This Year
Shareholders of Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) will be pleased this week, given that the stock price is up 14% to CN¥21.41 following its latest full-year results. Jiangsu K
Kangyuan Pharmaceutical (600557.SH)'s net profit in 2023 increased by 23.54% to $537 million, with a dividend of 0.37 yuan per share
Gelonghui, March 10 | Kangyuan Pharmaceutical (600557.SH) announced that in 2023, the company's annual business performance will steadily improve, breaking the game through reforms and constructing a new trend of high-quality development for the company. During the reporting period, the company's consolidated statements achieved operating income of 4.868 billion yuan, up 11.88% year on year, and net profit attributable to shareholders of listed companies of 537 million yuan, an increase of 23.54% year on year. The company plans to distribute a cash dividend of 0.37 yuan (tax included) per share to all shareholders, no bonus shares, and no capital increase from the capital reserve fund.
Kangyuan Pharmaceutical (600557.SH): A total of 849,300 shares have been repurchased
Gelonghui, March 1, 丨 Kangyuan Pharmaceutical (600557.SH) announced that as of February 29, 2024, the company had repurchased a total of 849,300 shares through the Shanghai Stock Exchange system, accounting for about 0.15% of the company's total share capital. The highest transaction price purchased was 17.93 yuan/share, the minimum transaction price was 16.27 yuan/share, and the average repurchase price was 16.63 yuan/share. The total amount paid was 14,121,888.36 yuan (including transaction fees).
Kangyuan Pharmaceutical (600557.SH): Initial repurchase of 611,300 shares
Gelonghui, February 7, 丨 Kangyuan Pharmaceutical (600557.SH) announced that on February 7, 2024, the company repurchased 611,300 shares of the company's shares for the first time through centralized bidding. The repurchased shares accounted for 0.10% of the company's total share capital. The highest transaction price purchased was 16.82 yuan/share, the minimum transaction price was 16.27 yuan/share, and the average repurchase price was 16.48 yuan/share. The total amount paid was 10,074,476.26 yuan (including transaction fees).
Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) shareholders won't be pleased to see that the share price has had a very rough month, dropping 27% and undoing the prior period's positive performa
Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) Is Up But Financials Look Inconsistent: Which Way Is The Stock Headed?
Jiangsu Kanion PharmaceuticalLtd's (SHSE:600557) stock up by 5.5% over the past three months. Given that the stock prices usually follow long-term business performance, we wonder if the company's mi
Kangyuan Pharmaceutical (600557.SH) drug GMP compliance test results are “in line with the requirements”
Kangyuan Pharmaceutical (600557.SH) announced that the company recently received “Drug G...” issued by the Jiangsu Drug Administration
Kangyuan Pharmaceutical (600557.SH): Obtained the Jichuan-fried Granule Drug Registration Certificate
Gelonghui, January 2, Kangyuan Pharmaceutical (600557.SH) announced that the company recently received the “Drug Registration Certificate” for Jichuanfan granules issued by the State Drug Administration. As one of the commonly used clinical prescriptions in traditional Chinese medicine, Jichuanpan is used to treat people with kidney deficiency and constipation such as habitual constipation, constipation in old age, and constipation after childbirth. The clinical efficacy of Jichuanpan has been supported by evidence from many medical cases since ancient times. In modern times, extensive clinical and experimental studies have also been carried out. The research results have been learned from various traditional Chinese medicine textbooks, and the clinical recognition is high.
Jiangsu Kanion Pharmaceutical Co.,Ltd.'s (SHSE:600557) Market Cap Dropped CN¥819m Last Week; Private Companies Bore the Brunt
Key Insights Jiangsu Kanion PharmaceuticalLtd's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 10 investors
Kangyuan Pharmaceutical (600557.SH): The subsidiary won the bid of 94.44472 million yuan for the No. 1 building project of Kangyuan Pharmaceutical Science and Technology Park
On December 26, Kangyuan Pharmaceutical (600557.SH) announced that Kangyuan Pharmaceutical () announced that in order to meet the construction and R&D needs of the “National Key Laboratory for Process Control and Intelligent Manufacturing Technology of Traditional Chinese Medicine” (hereinafter referred to as the “National Key Laboratory”), Kangyuan Pharmaceutical Technology, a wholly-owned subsidiary of the company, plans to build a new “Kangyuan Pharmaceutical Science and Technology Park Project Building 1” in Nanjing Jiangning Pharmaceutical Science and Technology Park as an R&D site. Kangyuan Pharmaceutical Technology selected the construction unit through an invitation to tender and a reasonably low price bid evaluation method. Through procedures such as bidding, bid evaluation, and bid determination, it was confirmed that Nantong Mingyuan was the winning bidder for the project. The winning bid price was RMB 9,444.72
Analysis
Price Target
No Data
